Atenção!


O atendimento às questões referentes ao Repositório Institucional será interrompido entre os dias 20 de dezembro de 2024 a 5 de janeiro de 2025.

Pedimos a sua compreensão e aproveitamos para desejar boas festas!

 

Hybrid Magnetic Lipid-Based Nanoparticles for Cancer Therapy

dc.contributor.authorLuiz, Marcela Tavares [UNESP]
dc.contributor.authorDutra, Jessyca Aparecida Paes [UNESP]
dc.contributor.authorViegas, Juliana Santos Rosa
dc.contributor.authorde Araújo, Jennifer Thayanne Cavalcante [UNESP]
dc.contributor.authorTavares Junior, Alberto Gomes [UNESP]
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade do Porto
dc.date.accessioned2023-07-29T16:10:15Z
dc.date.available2023-07-29T16:10:15Z
dc.date.issued2023-03-01
dc.description.abstractCancer is one of the major public health problems worldwide. Despite the advances in cancer therapy, it remains a challenge due to the low specificity of treatment and the development of multidrug resistance mechanisms. To overcome these drawbacks, several drug delivery nanosystems have been investigated, among them, magnetic nanoparticles (MNP), especially superparamagnetic iron oxide nanoparticles (SPION), which have been applied for treating cancer. MNPs have the ability to be guided to the tumor microenvironment through an external applied magnetic field. Furthermore, in the presence of an alternating magnetic field (AMF) this nanocarrier can transform electromagnetic energy in heat (above 42 °C) through Néel and Brown relaxation, which makes it applicable for hyperthermia treatment. However, the low chemical and physical stability of MNPs makes their coating necessary. Thus, lipid-based nanoparticles, especially liposomes, have been used to encapsulate MNPs to improve their stability and enable their use as a cancer treatment. This review addresses the main features that make MNPs applicable for treating cancer and the most recent research in the nanomedicine field using hybrid magnetic lipid-based nanoparticles for this purpose.en
dc.description.affiliationSchool of Pharmaceutical Sciences São Paulo State University (UNESP), SP
dc.description.affiliationInstituto de Investigação e Inovação em Saúde Universidade do Porto
dc.description.affiliationUnespSchool of Pharmaceutical Sciences São Paulo State University (UNESP), SP
dc.identifierhttp://dx.doi.org/10.3390/pharmaceutics15030751
dc.identifier.citationPharmaceutics, v. 15, n. 3, 2023.
dc.identifier.doi10.3390/pharmaceutics15030751
dc.identifier.issn1999-4923
dc.identifier.scopus2-s2.0-85151741821
dc.identifier.urihttp://hdl.handle.net/11449/249827
dc.language.isoeng
dc.relation.ispartofPharmaceutics
dc.sourceScopus
dc.subjectliposomes
dc.subjectmagnetic hyperthermia
dc.subjectmicroemulsion
dc.subjectnanocarriers
dc.subjectnanoemulsion
dc.subjectnanostructured lipid carrier
dc.subjectsolid lipid nanoparticles
dc.titleHybrid Magnetic Lipid-Based Nanoparticles for Cancer Therapyen
dc.typeResenha
unesp.author.orcid0000-0002-8615-3758[3]
unesp.author.orcid0000-0002-6083-8177[5]
unesp.author.orcid0000-0002-6698-0545[6]
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos